SG11202005807QA - Glycolate oxidase inhibitors for the treatment of disease - Google Patents

Glycolate oxidase inhibitors for the treatment of disease

Info

Publication number: SG11202005807QA
Authority: SG; Singapore
Prior art keywords: disease; treatment; oxidase inhibitors; glycolate oxidase; glycolate
Prior art date: 2017-12-29

Application number

SG11202005807QA

Inventor

Bing Wang

Qi Chao

Original Assignee

Biomarin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-29

Filing date

2018-12-28

Publication date

2020-07-29

2018-12-28 Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc

2020-07-29 Publication of SG11202005807QA publication Critical patent/SG11202005807QA/en

Links

102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
108010062584 glycollate oxidase Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

SG11202005807QA 2017-12-29 2018-12-28 Glycolate oxidase inhibitors for the treatment of disease SG11202005807QA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762611995P	2017-12-29	2017-12-29
US201862765313P	2018-08-20	2018-08-20
PCT/US2018/067784 WO2019133770A2 (en)	2017-12-29	2018-12-28	Glycolate oxidase inhibitors for the treatment of disease

Publications (1)

Publication Number	Publication Date
SG11202005807QA true SG11202005807QA (en)	2020-07-29

Family

ID=65234672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202005807QA SG11202005807QA (en)	2017-12-29	2018-12-28	Glycolate oxidase inhibitors for the treatment of disease

Country Status (17)

Country	Link
US (3)	US11384055B2 (en)
EP (1)	EP3732167A2 (en)
JP (2)	JP7344878B2 (en)
KR (1)	KR20200112860A (en)
CN (6)	CN117126152A (en)
AR (1)	AR114070A1 (en)
AU (1)	AU2018395275A1 (en)
BR (1)	BR112020013073A2 (en)
CA (1)	CA3086401A1 (en)
CL (1)	CL2020001742A1 (en)
IL (3)	IL297802A (en)
MA (1)	MA51418A (en)
MX (6)	MX2020006414A (en)
PE (1)	PE20201500A1 (en)
SG (1)	SG11202005807QA (en)
TW (2)	TW202340155A (en)
WO (1)	WO2019133770A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW202340155A (en) *	2017-12-29	2023-10-16	美商拜奧馬林製藥公司	Glycolate oxidase inhibitors for the treatment of disease
US11389456B2 (en)	2018-02-23	2022-07-19	Oxalurx, Inc.	Compounds and methods for treating oxalate-related diseases
KR20210041564A (en) *	2018-07-06	2021-04-15	오판 바이오테크 인코포레이티드	Triazole glycolate oxidase inhibitor
EP4017490A4 (en) *	2019-08-22	2023-11-22	Oxalurx, Inc.	Compounds and methods for treating oxalate-related diseases
CA3155577A1 (en) *	2019-11-01	2021-05-06	GyanRx Sciences, Inc.	Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
AU2021205916A1 (en) *	2020-01-08	2022-08-25	Cantero Therapeutics, Inc.	Processes for preparing triazole glycolate oxidase inhibitors
WO2022002131A1 (en) *	2020-06-30	2022-01-06	苏州恩华生物医药科技有限公司	5-((1,2,3,4-tetrahydroisoquinoline-7-yl)amino)pyridin-2(1h)-one derivative and use thereof
WO2022066933A1 (en) *	2020-09-24	2022-03-31	Chinook Therapeutics Canada, Inc.	Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
CN114478210A (en) *	2022-02-26	2022-05-13	江苏壹药新材料有限公司	Synthetic method of 7-chloronaphthalene-2-formaldehyde
WO2023170024A1 (en) *	2022-03-11	2023-09-14	University Of Copenhagen	Camk2 modulators and their use in medicine
GB202213162D0 (en)	2022-09-08	2022-10-26	Cambridge Entpr Ltd	Prodrugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US149223A (en) *		1874-03-31		Improvement in axles for vehicles
DE2860722D1 (en) *	1977-11-10	1981-08-27	Beecham Group Plc	Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use
DE2757929A1 (en) *	1977-12-24	1979-07-05	Boehringer Sohn Ingelheim	Pyrido-triazolo-pyrimidinone derivs. - useful as long lasting oral anti-allergens for treating asthma, etc.
JPS5519292A (en) *	1978-07-24	1980-02-09	Beecham Group Ltd	Benzopyranotriazoles*their manufacture and medical composition containing them
DE2966444D1 (en)	1978-07-24	1984-01-05	Beecham Group Plc	Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them
US4431660A (en)	1979-06-11	1984-02-14	Merck & Co., Inc.	(4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4349561A (en) *	1979-11-05	1982-09-14	Merck & Co., Inc.	4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
DE3169772D1 (en) *	1980-01-19	1985-05-15	Beecham Group Plc	SUBSTITUTED BENZOPYRANOTRIAZOLES
IL61897A (en) *	1980-01-19	1984-01-31	Beecham Group Ltd	Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them
NZ199139A (en) *	1980-12-13	1985-01-31	Beecham Group Ltd	Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles
US4431652A (en)	1980-12-29	1984-02-14	Merck & Co., Inc.	4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4428956A (en) *	1980-12-29	1984-01-31	Merck & Co., Inc.	4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
JPS57158788A (en) *	1981-03-03	1982-09-30	Beecham Group Ltd	Novel compound, manufacture and medicinal composition containing same
WO1993017681A1 (en) *	1992-03-02	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
US6962936B2 (en) *	2001-04-27	2005-11-08	Vertex Pharmaceuticals Incorporated	Triazole-derived kinase inhibitors and uses thereof
JP4075357B2 (en)	2001-11-15	2008-04-16	宇部興産株式会社	4,5-disubstituted-1,2,3-triazole and process for producing the same
BR0317230A (en) *	2002-12-13	2005-10-25	Smithkline Beecham Corp	Compound, composition, methods of antagonizing a ccr-5 chemokine receptor activity, and treating a viral infection in a patient, and use of a compound
GB0329214D0 (en) *	2003-12-17	2004-01-21	Glaxo Group Ltd	Novel compounds
GB0603891D0 (en) *	2006-02-27	2006-04-05	Syngenta Ltd	Novel herbicides
WO2011140296A1 (en) *	2010-05-05	2011-11-10	Infinity Pharmaceuticals	Triazoles as inhibitors of fatty acid synthase
IN2014DN09348A (en) *	2012-06-20	2015-07-17	Hoffmann La Roche
KR101537296B1 (en) *	2012-10-26	2015-07-17	삼성전자 주식회사	A semiconductor nanocrystal, and a method of preparing the same
TW201418242A (en)	2012-10-26	2014-05-16	Du Pont	Substituted triazoles as herbicides
JP2017095366A (en)	2015-11-18	2017-06-01	持田製薬株式会社	Novel biaryl amide derivative
US20200262794A1 (en)	2015-12-07	2020-08-20	Wake Forest University Health Sciences	Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
CN105541796B (en)	2016-03-03	2017-11-14	武汉工程大学	A kind of synthetic method of the triazole Bipyridine compounds of NH 1,2,3
CN105669569B (en)	2016-03-03	2017-12-12	武汉工程大学	A kind of synthetic method of the triazole compounds of NH 1,2,3
TW202340155A (en) *	2017-12-29	2023-10-16	美商拜奧馬林製藥公司	Glycolate oxidase inhibitors for the treatment of disease
BR112021025781A2 (en) *	2019-06-19	2022-03-03	Biomarin Pharm Inc	Compound, pharmaceutical composition, method of treating a disease or disorder associated with a defect in glyoxylate metabolism, method of treating a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism, and method for inhibiting the go enzyme

2018
- 2018-12-28 TW TW112107812A patent/TW202340155A/en unknown
- 2018-12-28 CN CN202310936668.6A patent/CN117126152A/en active Pending
- 2018-12-28 CN CN201880090533.XA patent/CN111788187A/en active Pending
- 2018-12-28 EP EP18840000.6A patent/EP3732167A2/en active Pending
- 2018-12-28 AR ARP180103914A patent/AR114070A1/en unknown
- 2018-12-28 MX MX2020006414A patent/MX2020006414A/en unknown
- 2018-12-28 TW TW107147699A patent/TWI811282B/en active
- 2018-12-28 MA MA051418A patent/MA51418A/en unknown
- 2018-12-28 KR KR1020207022038A patent/KR20200112860A/en not_active Application Discontinuation
- 2018-12-28 BR BR112020013073-7A patent/BR112020013073A2/en unknown
- 2018-12-28 CN CN202310936523.6A patent/CN117069712A/en active Pending
- 2018-12-28 CA CA3086401A patent/CA3086401A1/en active Pending
- 2018-12-28 US US16/958,511 patent/US11384055B2/en active Active
- 2018-12-28 AU AU2018395275A patent/AU2018395275A1/en active Pending
- 2018-12-28 CN CN202310936604.6A patent/CN117024420A/en active Pending
- 2018-12-28 JP JP2020535997A patent/JP7344878B2/en active Active
- 2018-12-28 WO PCT/US2018/067784 patent/WO2019133770A2/en active Application Filing
- 2018-12-28 CN CN202310936652.5A patent/CN117069713A/en active Pending
- 2018-12-28 CN CN202310936618.8A patent/CN117126151A/en active Pending
- 2018-12-28 IL IL297802A patent/IL297802A/en unknown
- 2018-12-28 SG SG11202005807QA patent/SG11202005807QA/en unknown
- 2018-12-28 IL IL297788A patent/IL297788A/en unknown
- 2018-12-28 PE PE2020000860A patent/PE20201500A1/en unknown
2020
- 2020-06-18 IL IL275496A patent/IL275496A/en unknown
- 2020-06-25 CL CL2020001742A patent/CL2020001742A1/en unknown
- 2020-07-13 MX MX2022016463A patent/MX2022016463A/en unknown
- 2020-07-13 MX MX2022016415A patent/MX2022016415A/en unknown
- 2020-07-13 MX MX2022016427A patent/MX2022016427A/en unknown
- 2020-07-13 MX MX2022016434A patent/MX2022016434A/en unknown
- 2020-07-13 MX MX2022016422A patent/MX2022016422A/en unknown
2022
- 2022-05-23 US US17/751,136 patent/US20230079913A1/en active Pending
- 2022-05-23 US US17/751,144 patent/US20230089374A1/en active Pending
2023
- 2023-08-04 JP JP2023127874A patent/JP2023159181A/en active Pending

Also Published As

Publication number	Publication date
WO2019133770A3 (en)	2019-08-15
IL297788A (en)	2022-12-01
JP7344878B2 (en)	2023-09-14
JP2021509401A (en)	2021-03-25
RU2020120974A (en)	2022-01-31
EP3732167A2 (en)	2020-11-04
PE20201500A1 (en)	2020-12-29
TW201930272A (en)	2019-08-01
TWI811282B (en)	2023-08-11
MX2020006414A (en)	2020-09-17
WO2019133770A2 (en)	2019-07-04
IL297802A (en)	2022-12-01
IL275496A (en)	2020-08-31
AU2018395275A1 (en)	2020-07-16
RU2020120974A3 (en)	2022-01-31
CN117024420A (en)	2023-11-10
MX2022016427A (en)	2023-01-30
CN117126151A (en)	2023-11-28
CL2020001742A1 (en)	2021-01-29
US20230089374A1 (en)	2023-03-23
BR112020013073A2 (en)	2020-12-01
CN117126152A (en)	2023-11-28
CN111788187A (en)	2020-10-16
CN117069712A (en)	2023-11-17
US20230079913A1 (en)	2023-03-16
US11384055B2 (en)	2022-07-12
KR20200112860A (en)	2020-10-05
TW202340155A (en)	2023-10-16
MA51418A (en)	2020-11-04
US20210171474A1 (en)	2021-06-10
JP2023159181A (en)	2023-10-31
MX2022016434A (en)	2023-01-30
CA3086401A1 (en)	2019-07-04
AR114070A1 (en)	2020-07-15
MX2022016415A (en)	2023-01-30
CN117069713A (en)	2023-11-17
MX2022016422A (en)	2023-01-30
MX2022016463A (en)	2023-02-01

Publication	Publication Date	Title
IL275496A (en)	2020-08-31	Glycolate oxidase inhibitors for the treatment of disease
IL253945B (en)	2021-05-31	Kdm1a inhibitors for the treatment of disease
IL279260A (en)	2021-01-31	Kdm1a inhibitors for the treatment of disease
IL275482A (en)	2020-08-31	Esketamine for the treatment of depression
ZA201703003B (en)	2018-04-25	Heparan sulfate biosynthesis inhibitors for the treatment of diseases
GB201804514D0 (en)	2018-05-02	Treatment of pyroptosis
IL288920A (en)	2022-02-01	Glycolate oxidase inhibitors for the treatment of disease
IL278247B (en)	2021-12-01	Mct4 inhibitors for treating disease
IL254266B (en)	2020-06-30	Glucosylceramide synthase inhibitors for the treatment of diseases
HK1253238A1 (en)	2019-06-14	Gls1 inhibitors for treating disease
PT3297628T (en)	2021-08-16	Calcineurin inhibitors of the setron family for the treatment of hearing loss
IL283948A (en)	2021-07-29	Methods for the treatment of depression
IL259297A (en)	2018-07-31	Heterocyclic compounds for the treatment of disease
PT3297625T (en)	2022-09-27	Compound for the prophylaxis or treatment of organ damage
GB201804515D0 (en)	2018-05-02	Treatment of necroptosis
EP3638252A4 (en)	2021-03-10	Sting-dependent activators for treatment of disease
IL283885A (en)	2021-07-29	Cxcr7 inhibitors for the treatment of cancer
PL3484475T3 (en)	2024-03-11	1-methylnicotinamide for the treatment of cardiovascular disease
IL274747A (en)	2020-07-30	Fxr agonists for the treatment of liver diseases
GB201614415D0 (en)	2016-10-05	Enzymes for the treatment of human enterometabolic dysfunction
PL3292226T3 (en)	2020-10-19	Method for the treatment of iron-containing sludge
PL3630754T3 (en)	2022-10-24	Isoindoline-acetylene compounds for the treatment of cancer
IL272124A (en)	2020-03-31	Treatment of non-inflammatory lesions
IL272422A (en)	2020-03-31	Methods for the treatment of leptomeningeal disease
HK1250343A1 (en)	2018-12-14	Calcineurin inhibitors of the setron family for the treatment of hearing loss